Patient has a concurrent malignancy or malignancy within  years of treatment start, with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer
Concurrent malignancy or a malignancy within  years prior to starting study drug, with the exception of adequately treated basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer; participants with malignancies less than  years prior to registration may be considered eligible after discussion with the principle investigator
Concurrent malignancy or malignancy within  years of study entry, with the exception of adequately treated basal or squamous cell carcinoma, non-melanomatous skin cancer or treated cervical cancer
Patient has a concurrent malignancy or malignancy within  years of randomization, with the exception of adequately treated non-melanomatous skin cancer and superficial bladder cancer (including carcinoma-in-situ)
Participant has a concurrent malignancy or malignancy within  years of enrollment, with the exception of adequately treated basal or squamous cell carcinoma, non-melanomatous skin cancer, or curatively resected cervical cancer.
Patient has a concurrent malignancy or malignancy within  years prior to starting study drug, with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer
Patient has a concurrent malignancy or malignancy within  years prior to starting study drug, with the exception of adequately treated, basal or squamous cell carcinoma, nonmelanomatous skin cancer or curatively resected cervical cancer
Previous or concurrent malignancy (with the exception of non-melanomatous skin cancer) within  years of the date of the consent
Concurrent malignancy or malignancy within  years prior to starting study drug, with the exception of adequately treated basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer
Presence of a concurrent malignancy or malignancy diagnosed within  years of randomization, with the exception of basal or squamous cell carcinoma, non-melanomatous skin cancer, curatively resected cervical cancer, localized prostate cancer treated with curative intent, and stage I colorectal cancer treated with curative resection
Patient has a concurrent malignancy or malignancy within  years prior to starting study drug, with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer
Patient has a concurrent malignancy or malignancy within  years prior to starting study drug, with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer
Previous or concurrent malignancy within the last  years with the exception of adequately treated skin basal or squamous cell with adequate wound healing
Patient has a concurrent malignancy or malignancy within  years of study screening period, with the exception of adequately treated, basal or squamous cell carcinoma, non-melanoma skin cancer or curatively resected cervical cancer
Patient has a concurrent malignancy or malignancy within  years of starting study drug, with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer
Subject has a concurrent malignancy or malignancy within  years of study enrollment (with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer)
Concurrent other malignancy with the exception of: \r\n* Cutaneous squamous cell and basal carcinomas\r\n* Adequately treated stage - malignancy\r\n* Adequately treated stage - malignancy that has been in remission for >=  years at the time of registration
Subject has a concurrent malignancy or malignancy within  years of study enrollment (with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer or prior ovarian/breast cancer in patients with BRCA associated breast cancer)
Patient has a concurrent malignancy or has a malignancy within  years of study enrollment (with the exception of adequately treated basal or squamous cell carcinoma or non-melanomatous skin cancer)
Patient has a concurrent malignancy or malignancy within  years of randomization, with the exception of adequately treated basal cell skin carcinoma, squamous cell skin carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer.
Patient has a concurrent malignancy or malignancy within  years prior to starting study drug, with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer
Patient has a concurrent malignancy or malignancy within  years prior to starting study drug, with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer.
Concurrent other malignancy with the exception of: a) cutaneous squamous cell and basal carcinomas, b) adequately treated stage - malignancy, c) adequately treated stage - malignancy that had been in remission for >=  years at the time of registration
Patient has a concurrent malignancy or malignancy within  years of randomization, with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer.
Patients with presence of concurrent or active malignant disease (other than disease under study) within the last  months with the exception of adequately treated in-situ carcinomas, basal or squamous cell carcinoma, or non-melanomatous skin cancer.
Patient has a concurrent malignancy or has a malignancy within  years of study enrollment (with the exception of adequately treated basal or squamous cell carcinoma or non-melanomatous skin cancer).
Patient has any tumor progression after definitive GBM resection/ biopsy, except for the transformation from previous low grade glioma. Patient with a concurrent malignancy or malignancy within  years of study enrollment (with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer)